Guardant Health Inc.
Guardant Health Reports 39% Revenue Growth for 2025 and Outlook for 2026
Summary
Guardant Health, Inc. reported a 39% increase in fourth quarter revenue for 2025, reaching $281.3 million, and a 33% increase for the full year 2025, reaching $982.0 million. The company expects revenue growth in the range of 27% to 30% for 2026. Key highlights include strong performance in oncology and screening segments, and the launch of new products and partnerships. Guardant Health also provided financial guidance for 2026, anticipating continued growth in revenue and oncology volume.
Profitelligence Alerts
Get alerts for GH
Be first to know when Guardant Health Inc. files with the SEC.
Filing Categories
Advertisement
About Guardant Health Inc.
Guardant Health Inc. is an innovative biotechnology company specializing in the development and commercialization of precision oncology diagnostics. This company is recognized for its groundbreaking work in non-invasive cancer detection through liquid biopsy technologies, which involve analyzing circulating tumor DNA in blood samples. Guardant Health’s primary function is to provide oncologists and researchers with critical tools and data to better understand cancer, tailor treatments, and monitor disease progression, potentially improving patient outcomes significantly. Guardant Health operates prominently in the healthcare and biotechnology sector, significantly impacting fields such as cancer research and personalized medicine. Their products and services are vital for facilitating early detection of cancer, identifying treatment options, and offering companion diagnostics for pharmaceutical developments. In the financial market, Guardant Health represents an important player within the precision medicine landscape, influencing investment within the biotechnology and healthcare sectors. Founded in 2012 and headquartered in Redwood City, California, the company continues to expand its portfolio and advance its technologies, playing a pivotal role in the fight against cancer at a global level.
Official SEC Documents
Advertisement